AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01119963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-alpha-hydroxy-progesterone caproate, Makena®
Description: Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
Study NCT01119963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Castor Oil (Placebo)
Description: IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
Study NCT01039311 — intervention group
Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Obtain OCT images.
Study NCT02411513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFALY
Study NCT04030468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention addressed to general practitioners
Description: * feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course
Study NCT04030468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative intervention addressed to patients
Description: • leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
Study NCT04319445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness session(s)
Description: The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
Study NCT00519883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT00519883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Study NCT04645004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 81Mg Non-enteric coated Tab
Description: one tab daily
Study NCT03224104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02
Description: The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated.
Study NCT03224104 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
Study NCT03224104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
Study NCT03771781 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin Tablets
Description: Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
Study NCT03771781 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin Tab 25 MG
Description: Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
Study NCT04401085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 diagnostic rapid test
Description: The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
Study NCT01496144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy and active exercises
Description: Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises
Study NCT04401085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of SARS-CoV-2 antibodies
Description: The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
Study NCT01496144 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Detuned ultrasound and active exercises
Description: Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
Study NCT03476967 — intervention group
Intervention type: PROCEDURE
Intervention: Panretinal photocoagulation
Description: In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
Study NCT03788616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuji IX EXTRA
Description: High-viscosity glass ionomer (Fuji IX EXTRA)
Study NCT03788616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVA KIDS bioactive restorative material
Description: Modified composite (ACTIVA KIDS)
Study NCT00621010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS21166 (ZPQ-21166)
Description: Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion
Study NCT00246376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: ATP-III diet
Study NCT00246376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise in study gym
Study NCT00246376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Niaspan, titrated up to 2 grams per day
Study NCT00246376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Tricor, 120 mg per day
Study NCT00246376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos for Niaspan and Tricor
Study NCT00246376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos for Niaspan and Tricor
Study NCT02923050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Suppers
Description: Theory-based 10-week family meals program
Study NCT00873145 — intervention group
Intervention type: PROCEDURE
Intervention: HMRS
Description: Modular prosthetic replacement of the humerus and elbow.
Study NCT03932019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jitongning tablet(High-dose )
Description: Jitongning tablet,3tablets,bid,treat 12 weeks
Study NCT03932019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jitongning tablet(Low-dose )
Description: Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
Study NCT03932019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Jitongning tablet placebo,3tablets,bid,treat 12 weeks
Study NCT03412123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group lifestyle-integrated functional exercise
Description: Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
Study NCT03523949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE
Description: The PNE will be delivered by a physiotherapist in a single, group-based session.
Study NCT03352128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will have to supplement themselves with creatine for 7 days (20g/day).
Study NCT03352128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium lactate
Description: Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
Study NCT04572893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danicamtiv
Description: Myosin activator
Study NCT02666690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEUS (Contrast-enhanced ultrasound)
Description: Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
Study NCT01544478 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V501
Description: HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
Study NCT02019745 — intervention group
Intervention type: BIOLOGICAL
Intervention: LAIV
Description: Standard dose of LAIV administered by a licensed health care providers.
Study NCT00250497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Moves
Description: The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
Study NCT01082003 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trental
Description: Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
Study NCT03429764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CISS
Description: continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
Study NCT03429764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VIMS
Description: internal mattress suture will be placed with minimum two intact contact points at the surgical site
Study NCT04393909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Uncertainty Educational Curriculum
Description: A Diagnostic Uncertainty Educational Curriculum will consist of an interactive, one-hour teach-the-teacher workshop delivered to resident-attending pairs early on during their inpatient medicine rotation. During the workshop, we will discuss the motivation behind teaching diagnostic uncertainty, review factors that may predict risk of diagnostic error during hospitalization, introduce the framework. Each resident-attending pair will work through a case-based exercise focused on managing learners' diagnostic uncertainty during rounds. Our research team will also conduct Training for clinical staff working on intervention units and will provide at-the-elbow support during the intervention period of the main trial.
Study NCT04393909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Timeout
Description: A Diagnostic Timeout is a structured pocket guide that clinicians may use to address uncertainty in a step-wise approach for patients who have risk factors for diagnostic error. This tool can be used during or after clinical rounds, inside or outside of a patient's room if the patient is agreeable. The Diagnostic Timeout will be introduced as part of the Diagnostic Uncertainty Educational Curriculum as well as Training.
Study NCT04393909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Diagnostic (Dx) Questionnaire
Description: We will administer a survey, the Dx Questionnaire, to patients which asks a series of questions on communication regarding diagnosis with the care team. Patients admitted to inpatient units within the prior 24 hours will be approached after asking the patient's nurse to determine whether it is the appropriate time to approach for enrollment. Upon explaining the objectives of the survey and obtaining verbal informed consent, patients will be asked to complete the Dx Questionnaire via REDCap on an iPad. Alternatively, the research assistant administering the survey will go through the Dx Questionnaire with the patient and record their answers in REDCap on their behalf. If patients' answers indicate a gap in communication (i.e., an answer of No on a question), the Research Assistant will ask for permission to follow-up within the next few days and will relay the gap in communication to the patients' care team (i.e., nurse).
Study NCT04393909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancements to Epic-integrated Quality & Safety Dashboard
Description: Epic-integrated Quality and Safety Dashboard, currently in operational use at BWH, will be enhanced to include a new diagnostic safety column. Clinical staff will receive Training and at-the-elbow support by the research team upon implementation.
Study NCT03891615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage.
Study NCT03891615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
Study NCT04758741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Investigating the impact of Acceptance and Commitment Therapy on Resiliency in women affected by domestic violence
Study NCT04758741 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: This rct has one arm and health education is done only for the purpose of blinding the study so that the participant does not know which of the control or intervention groups it is in and has no comparative aspect and has nothing to do with resilience
Study NCT00300534 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Abbott Laboratories Determine test for syphilis
Study NCT00300534 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Investigational syphilis immunochromatographic strip test
Study NCT01591811 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 1 Daily Boost of Radiation Therapy
Description: Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
Study NCT03486548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine and dexamethasone
Description: adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
Study NCT01591811 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm 2 Weekly Boost of Radiation Therapy
Description: Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
Study NCT04327050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic anchored guided endoscopic submucosal dissection
Description: Using magnetic anchoring technology, the magnetic pulling unit is anchored to the abdominal wall, and micro surgical tweezers are used. The tumor tissue is pulled indirectly, so that the mucosa is lifted up, which is beneficial to the peeling of the submucosa.
Study NCT01759355 — intervention group
Intervention type: PROCEDURE
Intervention: FDG PET/MR
Description: Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
Study NCT00882830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EMS
Description: EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
Study NCT01496404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery
Description: Electrocautery using cutting mode of epidermis and dermis of skin.
Study NCT01496404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Incising skin (epidermis and dermis) with scalpel.
Study NCT04500067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Patients in the study group receive the drug Bioven, 10% solution for infusions produced by LLC Biopharma Plasma 0,8-1,0 g/kg once a day for 2 days (total course dose - 1.6-2.0 g/kg) as well as base treatment recommended by the protocol of COVID-19 coronavirus infection treatment depending on the severity of their condition according to the prescription sheet.
Study NCT03486548 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: bupivacaine and lidocaine
Description: adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
Study NCT03486548 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: ultrasound
Study NCT03486548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: ultrasound
Study NCT02845505 — intervention group
Intervention type: OTHER
Intervention: Intravascular Ultrasound, coronary computed tomography angiography
Study NCT03416530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
Study NCT04170816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: DN and KT therapy will be applied 3 sessions in 1-week intervals
Study NCT04730284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health supplements
Description: tailor-made Synbiotics, 4g per day for 28 days
Study NCT04012983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid level
Description: gingival crevicular fluid collection
Study NCT04362982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.
Description: Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
Study NCT04362982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADHD360 platform: An intervention intergrating a serious game along with a mobile application for daily behavioral monitoring.
Description: Clinical trials will include two parts. The first part includes three visits. In the first visit, children and their parents will come to the Laboratory of Medical Physics to be informed regarding the experimental procedures, sign the consent form and familiarize with the scientific staff involved in the project as well as the lab enviroment. In the second visit, children will undergo an neuropsychological assessment delivered by an experienced pscychologist. Afterwards, they will interact with the ADHD360 platfrom for 30-45 minutes. In the third visit, participants will interact with the ADHD360 platfrom for 30-45 minutes. In the second part, participants will use the ADHD360 platfrom two or three times per week for about 30-45 minutes. At the end of the second part, participants will undergo a neuropsychological evalutation following the same procedures as the first one.
Study NCT02092493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ScopeGuide
Description: These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
Study NCT02568800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged Cefepime Infusion
Description: Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
Study NCT04334772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle belly Microelectrolysis
Description: three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application at the level of the muscular belly of the shortened hamstrings.